Grant Terminations at National Institutes of Health Disproportionately Affect Minority Scientists

In a revealing new study published in The Lancet Regional Health – Americas, researchers at the University of California San Diego uncover a troubling pattern in recent funding cuts by the National Institutes of Health (NIH). The study reveals that the abrupt termination of over 2,000 NIH grants between January and May 2025 disproportionately impacted scientists from marginalized communities, particularly those engaged in health equity and gender identity research. This shift in research financing threatens to exacerbate extant disparities within the U.S. biomedical research landscape, impeding scientific progress on issues vital to vulnerable populations.

The NIH, with an annual investment exceeding $47 billion, is the largest single source of public funding for biomedical research worldwide. Its funding priorities not only shape the trajectory of scientific inquiry in the United States but have global ramifications. As such, sudden realignments in NIH funding allocations can result in significant disruptions, reverberating across scientific disciplines. This recent wave of grant terminations was driven by a strategic recalibration of agency priorities, culminating in a sweeping cancellation of projects focusing on health disparities and related domains.

Notably, the affected grants prominently included those investigating the health of Black, Indigenous, and People of Color (BIPOC) communities, as well as sexual and gender minorities. Beyond mere representation, the data indicate a systemic targeting, where researchers from these groups were often singled out in ways that magnified the impact of these funding cuts. For example, nearly half of investigators experiencing equity-related grant terminations identified as BIPOC, while 60% of those whose grants were canceled for gender-related reasons belonged to sexual and gender minority identities, with 16.5% identifying as transgender or nonbinary.

Such disparities are not trivial statistical observations but rather signals of deep structural inequities. The study found that BIPOC women and transgender or nonbinary researchers faced nearly triple the odds of having their grants terminated for equity-related reasons compared to their White male counterparts. Even more striking, sexual and gender minority researchers were more than 11 times likelier to experience gender-related funding termination than heterosexual, cisgender investigators. These figures underline the disproportionate vulnerability of marginalized scientists in the current funding landscape.

Surveying 941 scientists whose grants were canceled, using data from the Grant Witness database, the study employed an innovative classification system to understand termination reasons. Grant terminations linked to vague descriptors like “amorphous equity objectives” were coded as equity-related, while those citing “gender identity” were recorded as gender-related terminations. The study did not only focus on individual-level effects but also analyzed broader institutional actions, such as the cancelation of roughly 600 NIH grants tied to alleged campus antisemitism. Intriguingly, 20.5% of these institutional terminations involved scientists who self-identify as Jewish, casting doubt on the effectiveness and fairness of these policies.

This research builds on a growing body of literature documenting systemic disparities in biomedical research funding. Prior investigations have highlighted how scientists from underrepresented backgrounds disproportionately pursue community-centered and health disparities research, areas that have historically been underfunded. The latest findings suggest that the 2025 terminations risk deepening these inequities, both by interrupting individual careers and by curtailing the scope and diversity of scientific inquiry itself.

The consequences of these terminations extend well beyond the immediate loss of funding. Grant discontinuations disrupt active research projects, sever critical community partnerships, and stall the momentum of early-career investigators who rely heavily on continuous funding to build their professional trajectories. As academic success and grant acquisition are often cumulative processes, the impact of a single termination can resonate for years, potentially sidelining the expertise most vital for addressing pressing health equity challenges.

Importantly, the study’s senior author, Dr. Rebecca Fielding-Miller of UC San Diego’s Herbert Wertheim School of Public Health and Human Longevity Science, underscores the profound implications of these funding shifts. “These grant terminations didn’t just disrupt specific research projects; they also disrupted the careers of many scientists who study the health of marginalized communities,” she notes. The erasure of funding targeting equity-focused science undermines not only individual scientists but also the scientific enterprise’s capacity to interrogate and address health disparities.

The NIH’s funding realignment sends a chilling message about which scientific questions and communities are prioritized. Such decisions inherently shape the biomedical research agenda, influencing not only present investigations but also the future makeup of the biomedical workforce. As funding channels narrow for equity- and gender-related research, the diversity of research topics and investigators diminishes, compromising the inclusivity and breadth of scientific inquiry.

Going forward, the study authors advocate for the restoration and expansion of funding dedicated to equity-related health research. Only by ensuring continued support for researchers from marginalized communities can the biomedical field hope to maintain both a diverse workforce and a research agenda that fully reflects the health needs of all populations. The persistence of systemic bias against minority investigators threatens to entrench disparities further, creating a self-perpetuating cycle of underfunding and underrepresentation.

In a broader socio-political context, these findings raise urgent questions about the governance of science funding agencies. Transparent, equity-conscious funding processes are crucial to protect vulnerable researchers and uphold the integrity of scientific exploration. As the NIH is a bellwether for global scientific funding norms, its policies reverberate beyond U.S. borders, highlighting the imperative for inclusive and just research funding practices worldwide.

This landmark study is a clarion call to policymakers, scientific institutions, and funding bodies. It urges immediate attention to the unintended harms wrought by abrupt grant cancellations, particularly those that disproportionately silence the voices and expertise of minoritized researchers. Without corrective actions, the biomedical research enterprise risks alienating the very scientists most equipped to advance health equity and social justice through science.